Placebo Control

Maybe those pesky sites are good for something after all.  It's been six years since Pfizer boldly announced the launch of its "...

Near the end of last year, I had the bright idea of starting a second blog, Placebo Lead-In , to capture a lot of smaller items that I foun...

Are competing trials slowing yours down? Probably not. If they don't like your trial, EVERYTHING ELSE IN THE WORLD is competition fo...

Here's a fitting postscript to yesterday's article about wishful-thinking-based enrollment strategies : we received a note from a re...

The many flavors of wish-based patient recruitment. [Hopefully-obvious disclosure: I work in the field of clinical trial enrollment .] ...

'Competitive enrollment' is exactly that. This is a graph I tend to show frequently to my clients – it shows the relative enrollm...

ENACCT has released its final report on the outcomes from the National Cancer Clinical Trials Pilot Breakthrough Collaborative (NCCTBC) , a...

TransCelerate: Pharma's great kumbaya moment? Last week, 10 of the largest pharmaceutical companies caused quite a hullaballoo in t...

Pretty much everyone involved in patient recruitment for clinical trials seems to agree that "metrics" are, in some general sense,...